Clinical and preclinical studies have shown that the production of antibodies that inhibit the PD-1, PD-L1, and CTLA-4 checkpoints activate T cells and lead to Treg cell dysfunction, ultimately leading to the development of PAH (37–40). This evidence concerns the gene CTLA4 and pulmonary arterial hypertension.